N/A
N=29
Blueberries, Inflammation, Motivation, and Physical Activity
Depressive Symptoms
Bottom Line
View on ClinicalTrials.gov: NCT05735587 ↗Enrolled (actual)
29
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: Change in Engagement in Physical Activity — 318; 346 steps per day
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Freeze-dried Blueberry Powder (Other); Placebo Powder (Other)
- Age
- Older Adult · 65+ yrs
- Sex
- All
- Sponsor
- Hebrew SeniorLife
- Primary completion
- Jul 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Engagement in Physical Activity |
318; 346 | — |
| SECONDARY Study Recruitment Feasibility |
12; 10 | — |
| SECONDARY Change in Motivation |
4; 0 | — |
| SECONDARY Change in Inflammatory Marker - C-Reactive Protein |
0.6; -1.6 | — |
| SECONDARY Change in Inflammatory Marker - Interleukin-6 |
-0.5; -0.7 | — |
| SECONDARY Change in Inflammatory Marker - Brain Derived Neurotrophic Factor |
1.258; -1.226 | — |
Summary
The purpose of this study is to determine the feasibility and preliminary efficacy of daily supplementation of freeze-dried blueberry to modulate inflammation-driven lack of motivation in 40 sedentary, older adults with depressive symptoms.
Eligibility Criteria
Inclusion Criteria
- Men and women aged ≥65 years
- Self-reporting ≥ 8 hours of sitting per/day (e.g., sedentary behavior)
- Depressive symptoms (defined as ≥4 and 7,500 steps per day (as measured by the ActiGraph), or per discretion of the PI
- Cognitive impairment (defined as Montreal Cognitive Assessment, MoCA 2 points)
- Current alcohol use disorder (Alcohol Use Disorders Identification Test - Consumption, AUDIT-C≥4 points)
- Unstable anti-depressant use (e.g., change in medication within last 3-6 months), or per discretion of the PI
- Current homicidal or suicidal ideation (assessed via the P4 Suicidality Screener)
- Current psychosis (via the Psychosis and Hallucinations Questionnaire, PHQ>12 points)
- Manic symptoms (assessed by the Mood Disorder Questionnaire, MDQ >5 points)
Data sourced from ClinicalTrials.gov (NCT05735587). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.